Your browser doesn't support javascript.
loading
Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.
Blanquart, François; Wymant, Chris; Cornelissen, Marion; Gall, Astrid; Bakker, Margreet; Bezemer, Daniela; Hall, Matthew; Hillebregt, Mariska; Ong, Swee Hoe; Albert, Jan; Bannert, Norbert; Fellay, Jacques; Fransen, Katrien; Gourlay, Annabelle J; Grabowski, M Kate; Gunsenheimer-Bartmeyer, Barbara; Günthard, Huldrych F; Kivelä, Pia; Kouyos, Roger; Laeyendecker, Oliver; Liitsola, Kirsi; Meyer, Laurence; Porter, Kholoud; Ristola, Matti; van Sighem, Ard; Vanham, Guido; Berkhout, Ben; Kellam, Paul; Reiss, Peter; Fraser, Christophe.
Afiliación
  • Blanquart F; Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
  • Wymant C; Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
  • Cornelissen M; Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Gall A; Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
  • Bakker M; Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom.
  • Bezemer D; Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
  • Hall M; Stichting HIV Monitoring, Amsterdam, the Netherlands.
  • Hillebregt M; Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Ong SH; Stichting HIV Monitoring, Amsterdam, the Netherlands.
  • Albert J; Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom.
  • Bannert N; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Fellay J; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
  • Fransen K; Division for HIV and other Retroviruses, Robert Koch Institute, Berlin, Germany.
  • Gourlay AJ; School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
  • Grabowski MK; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Gunsenheimer-Bartmeyer B; HIV/STI reference laboratory, WHO collaborating centre, Institute of Tropical Medicine, Department of Clinical Science, Antwerpen, Belgium.
  • Günthard HF; Department of Infection and Population Health, University College London, London, United Kingdom.
  • Kivelä P; Department of Epidemiology, John Hopkins University, Baltimore, Maryland, United States of America.
  • Kouyos R; Department of Infectious Disease Epidemiology, Robert Koch-Institute, Berlin, Germany.
  • Laeyendecker O; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Liitsola K; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Meyer L; Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.
  • Porter K; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Ristola M; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • van Sighem A; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, United States of America.
  • Vanham G; Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland.
  • Berkhout B; INSERM CESP U1018, Université Paris Sud, Université Paris Saclay, APHP, Service de Santé Publique, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
  • Kellam P; Department of Infection and Population Health, University College London, London, United Kingdom.
  • Reiss P; Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland.
  • Fraser C; Stichting HIV Monitoring, Amsterdam, the Netherlands.
PLoS Biol ; 15(6): e2001855, 2017 Jun.
Article en En | MEDLINE | ID: mdl-28604782
ABSTRACT
HIV-1 set-point viral load-the approximately stable value of viraemia in the first years of chronic infection-is a strong predictor of clinical outcome and is highly variable across infected individuals. To better understand HIV-1 pathogenesis and the evolution of the viral population, we must quantify the heritability of set-point viral load, which is the fraction of variation in this phenotype attributable to viral genetic variation. However, current estimates of heritability vary widely, from 6% to 59%. Here we used a dataset of 2,028 seroconverters infected between 1985 and 2013 from 5 European countries (Belgium, Switzerland, France, the Netherlands and the United Kingdom) and estimated the heritability of set-point viral load at 31% (CI 15%-43%). Specifically, heritability was measured using models of character evolution describing how viral load evolves on the phylogeny of whole-genome viral sequences. In contrast to previous studies, (i) we measured viral loads using standardized assays on a sample collected in a strict time window of 6 to 24 months after infection, from which the viral genome was also sequenced; (ii) we compared 2 models of character evolution, the classical "Brownian motion" model and another model ("Ornstein-Uhlenbeck") that includes stabilising selection on viral load; (iii) we controlled for covariates, including age and sex, which may inflate estimates of heritability; and (iv) we developed a goodness of fit test based on the correlation of viral loads in cherries of the phylogenetic tree, showing that both models of character evolution fit the data well. An overall heritability of 31% (CI 15%-43%) is consistent with other studies based on regression of viral load in donor-recipient pairs. Thus, about a third of variation in HIV-1 virulence is attributable to viral genetic variation.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Variación Genética / Infecciones por VIH / VIH-1 / Seropositividad para VIH / Genoma Viral / Proteínas del Virus de la Inmunodeficiencia Humana / Modelos Genéticos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: PLoS Biol Asunto de la revista: BIOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Variación Genética / Infecciones por VIH / VIH-1 / Seropositividad para VIH / Genoma Viral / Proteínas del Virus de la Inmunodeficiencia Humana / Modelos Genéticos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: PLoS Biol Asunto de la revista: BIOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido